Halozyme Therapeutics (Halozyme Therapeutics) Change In Receivables

: $-3.3 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

Halozyme Therapeutics's change in receivables for the quarter that ended in Dec. 2023 was $-16.9 Mil. It means Halozyme Therapeutics's Accounts Receivable increased by $16.9 Mil from Sep. 2023 to Dec. 2023 .

Halozyme Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was $-3.3 Mil. It means Halozyme Therapeutics's Accounts Receivable increased by $3.3 Mil from Dec. 2022 to Dec. 2023 .

Halozyme Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2023 was $233.3 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Halozyme Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 92.53.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Halozyme Therapeutics's liquidation value for the three months ended in Dec. 2023 was $-1,074.7 Mil.

Halozyme Therapeutics Change In Receivables Historical Data

The historical data trend for Halozyme Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-29.44

-38.29

6.76

-83.94

-3.34

Halozyme Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables																-7.76	36.19	-51.50	28.85	-16.89

Halozyme Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.3 Mil.

Halozyme Therapeutics (NAS:HALO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Halozyme Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	233.254	/	230.039	*	91
=	92.53

2. In Ben Graham's calculation of liquidation value, Halozyme Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Halozyme Therapeutics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	336	-	1649.462	+	0.75 * 233.254	+	0.5 * 127.601
=	-1,074.7

Halozyme Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics (Halozyme Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (NAS:HALO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

RV7:Germany

Address

12390 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.halozyme.com

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Executives

Michael J. Labarre	officer: SVP, Chief Technical Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Helen Torley	director, officer: President and CEO	C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James M Daly	director	INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Jeffrey William Henderson	director	7000 CARDINAL PLACE, DUBLIN OH 43017
Nicole Labrosse	officer: SVP, Chief Financial Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Matthew L. Posard	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Akiko Moni Miyashita	director	20725 S. WESTERN AVENUE, SUITE 136, TORRANCE CA 90501
Mark Howard Snyder	officer: SVP, General Counsel	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Matsui Connie	director	3030 CALLAN RD, SAN DIEGO CA 92121
Jean-pierre Bizzari	director	235 LAUREL LN, HAVERFOLD PA 19041
Kenneth J Kelley	director	1331 HILLVIEW DRIVE, MENLO PARK CA 94025
Elaine D Sun	officer: SVP, Chief Financial Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Masaru Matsuda	officer: SVP, General Counsel	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Benjamin Hickey	officer: SVP, Chief Commerical Officer	C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121